ES2145774T3 - Derivados de adenosina que tienen actividad agonista en a2. - Google Patents
Derivados de adenosina que tienen actividad agonista en a2.Info
- Publication number
- ES2145774T3 ES2145774T3 ES93911492T ES93911492T ES2145774T3 ES 2145774 T3 ES2145774 T3 ES 2145774T3 ES 93911492 T ES93911492 T ES 93911492T ES 93911492 T ES93911492 T ES 93911492T ES 2145774 T3 ES2145774 T3 ES 2145774T3
- Authority
- ES
- Spain
- Prior art keywords
- agonist activity
- adenosine derivatives
- adenosine
- derivatives
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 150000003835 adenosine derivatives Chemical class 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
DERIVADOS DE LA ADENOSINA QUE TIENEN UNA ACTIVIDAD AGONISTA A2 DE FORMULA (I), UN PROCESO PARA LA PREPARACION DE LOS MISMOS Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN. LOS COMPUESTOS DE LA INVENCION SON UTILES PARA EL TRATAMIENTO DE PATOLOGIAS CARDIOVASCULARES Y DE ENFERMEDADES DEL SISTEMA NERVIOSO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI920973A IT1254915B (it) | 1992-04-24 | 1992-04-24 | Derivati di adenosina ad attivita' a2 agonista |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2145774T3 true ES2145774T3 (es) | 2000-07-16 |
Family
ID=11363039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93911492T Expired - Lifetime ES2145774T3 (es) | 1992-04-24 | 1993-04-21 | Derivados de adenosina que tienen actividad agonista en a2. |
Country Status (9)
Country | Link |
---|---|
US (1) | US5593975A (es) |
EP (1) | EP0637315B1 (es) |
JP (1) | JPH07508718A (es) |
AT (1) | ATE193299T1 (es) |
CA (1) | CA2134067A1 (es) |
DE (1) | DE69328722T2 (es) |
ES (1) | ES2145774T3 (es) |
IT (1) | IT1254915B (es) |
WO (1) | WO1993022328A1 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
GB9813540D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
JP2002173427A (ja) * | 1998-09-01 | 2002-06-21 | Yamasa Shoyu Co Ltd | 眼疾患治療用医薬組成物 |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
WO2000044763A2 (en) * | 1999-02-01 | 2000-08-03 | University Of Virginia Patent Foundation | Compositions for treating inflammatory response |
US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
US6180615B1 (en) | 1999-06-22 | 2001-01-30 | Cv Therapeutics, Inc. | Propargyl phenyl ether A2A receptor agonists |
GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
CA2439222C (en) * | 2000-02-23 | 2009-07-14 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
AU2001278708A1 (en) * | 2000-09-08 | 2002-03-22 | Toa Eiyo Ltd. | Adenosine derivatives and use thereof |
US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
BR0206464A (pt) * | 2001-01-16 | 2005-01-18 | Vascular Therapies Llc | Aparelho e processos para impedir ou tratar insuficiência de acesso vascular para hemodiálise e outros enxertos vasculares |
CA2460911C (en) * | 2001-10-01 | 2011-08-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
GB0129273D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Crystalline drug form |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
US7683037B2 (en) * | 2002-07-29 | 2010-03-23 | Gilead Palo Alto, Inc. | Myocardial perfusion imaging method |
US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
US20050033044A1 (en) | 2003-05-19 | 2005-02-10 | Bristol-Myers Squibb Pharma Company | Methods for preparing 2-alkynyladenosine derivatives |
CA2544193C (en) * | 2003-10-31 | 2012-03-27 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
TWI346109B (en) * | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
US7576069B2 (en) | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
US7442687B2 (en) * | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
NZ585697A (en) * | 2004-08-02 | 2011-12-22 | Univ Virginia Patent Found | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
US7655636B2 (en) * | 2004-10-20 | 2010-02-02 | Gilead Palo Alto, Inc. | Use of A2A adenosine receptor agonists |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
EP1989214B8 (en) | 2006-02-03 | 2016-12-21 | Gilead Sciences, Inc. | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
WO2007092936A2 (en) * | 2006-02-08 | 2007-08-16 | University Of Virginia Patent Foundation | Method to treat gastric lesions |
WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
AR060607A1 (es) | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
JP2009541354A (ja) * | 2006-06-22 | 2009-11-26 | シーブイ・セラピューティクス・インコーポレイテッド | 虚血の治療におけるa2aアデノシン受容体アゴニストの使用 |
EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
EP2056834B1 (en) * | 2006-09-01 | 2012-08-29 | Gilead Sciences, Inc. | Methods and compositions for increasing patient tolerability during myocardial imaging methods |
US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
WO2008042796A2 (en) * | 2006-09-29 | 2008-04-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
WO2008086096A2 (en) * | 2007-01-03 | 2008-07-17 | Cv Therapeutics, Inc. | Myocardial perfusion imaging |
US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
JP2011513493A (ja) | 2008-03-10 | 2011-04-28 | コーネル ユニバーシティー | 血液脳関門透過性の調節方法 |
MX2011003168A (es) * | 2008-09-29 | 2011-05-19 | Gilead Sciences Inc | Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples. |
EA201270102A1 (ru) | 2009-06-30 | 2012-08-30 | Форест Лэборетериз Холдингз Лимитед | Соединения алкокси-карбонил-амино-алкинил-аденозина и их производные в качестве агонистов ar |
KR20150036767A (ko) | 2012-08-01 | 2015-04-07 | 루이스 앤드 클라크 파마슈티컬스, 인코포레이티드 | A2a 효능제로서의 n-알킬 2-(이치환된)알키닐아데노신-5-유론아미드 |
US9822141B2 (en) | 2012-08-01 | 2017-11-21 | Lewis And Clark Pharmaceuticals, Inc. | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6299395A (ja) * | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | 2−アルキニルアデノシンおよび抗高血圧剤 |
IL84414A0 (en) * | 1986-11-14 | 1988-04-29 | Ciba Geigy Ag | N9-cyclopentyl-substituted adenine derivatives |
EP0277917A3 (en) * | 1987-02-04 | 1990-03-28 | Ciba-Geigy Ag | Certain adenosine 5'-carboxamide derivatives |
LU87181A1 (fr) * | 1987-04-06 | 1988-11-17 | Sandoz Sa | Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments |
US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
ZA902280B (en) * | 1989-03-29 | 1990-12-28 | Merrell Dow Pharma | Selective adenosine receptor agents |
-
1992
- 1992-04-24 IT ITMI920973A patent/IT1254915B/it active IP Right Grant
-
1993
- 1993-04-21 JP JP5518886A patent/JPH07508718A/ja active Pending
- 1993-04-21 EP EP93911492A patent/EP0637315B1/en not_active Expired - Lifetime
- 1993-04-21 ES ES93911492T patent/ES2145774T3/es not_active Expired - Lifetime
- 1993-04-21 AT AT93911492T patent/ATE193299T1/de active
- 1993-04-21 DE DE69328722T patent/DE69328722T2/de not_active Expired - Fee Related
- 1993-04-21 US US08/325,201 patent/US5593975A/en not_active Expired - Lifetime
- 1993-04-21 WO PCT/EP1993/000972 patent/WO1993022328A1/en active IP Right Grant
- 1993-04-21 CA CA002134067A patent/CA2134067A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IT1254915B (it) | 1995-10-11 |
DE69328722T2 (de) | 2000-12-14 |
ITMI920973A0 (it) | 1992-04-24 |
US5593975A (en) | 1997-01-14 |
ITMI920973A1 (it) | 1993-10-24 |
DE69328722D1 (de) | 2000-06-29 |
EP0637315B1 (en) | 2000-05-24 |
EP0637315A1 (en) | 1995-02-08 |
ATE193299T1 (de) | 2000-06-15 |
WO1993022328A1 (en) | 1993-11-11 |
JPH07508718A (ja) | 1995-09-28 |
CA2134067A1 (en) | 1993-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2145774T3 (es) | Derivados de adenosina que tienen actividad agonista en a2. | |
SV1998000029A (es) | Compuestos de pirazina ref. pg3186 | |
GT199700095A (es) | Derivados 6,5-heterobiciclicos sustituidos. | |
AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
MX9301348A (es) | Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende. | |
ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
ES2139959T3 (es) | Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2. | |
ES2095432T3 (es) | Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
ES2144192T3 (es) | Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
AR001332A1 (es) | Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen. | |
ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
PA8452001A1 (es) | Derivados de macrolidos c-4" sustituidos | |
PT1207756E (pt) | Utilizacao de espinosade ou de uma formulacao que compreende espinosade | |
AR004700A1 (es) | 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento | |
AR010700A1 (es) | Derivados de purina sustituidos, procedimiento para su preparacion, su empleo y su agente que los contiene | |
AR019496A1 (es) | Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos | |
HN2003000272A (es) | Formulaciones que comprenden un compuesto de indolinona | |
PA8457001A1 (es) | Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol | |
NO933524L (no) | Krystallisk tiagabinhydrokloridmonohydrat samt fremstilling og anvendelse derav | |
IT8123940A0 (it) | Derivati della s-adenosilmetionina, processo per la loro preparazione e composizioni terapeutiche che licontengono come principio attivo. | |
AR021843A1 (es) | Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion. | |
MX9301157A (es) | Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
MX9203361A (es) | Composiciones farmaceuticas que contienen cloruro de galio. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 637315 Country of ref document: ES |